account
From EyewireToday.com — 11/11/2011
Retina
The FDA stated that it was unable to approve a new drug application for Iluvien (fluocinolone acetonide, Alimera Sciences) because the application did not provide sufficient data to support that Iluvien is safe and effective in the treatment of patients with Diabetic Macular Edema (DME). The FDA stated that the risks of adverse reactions...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to FDA Rejects Alimera’s Request for NDA Approval of Iluvien
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account